glucagon like peptide 1 glp 1 receptor agonist medications Glucagon-like 1(GLP-1) agonists in the management of the patient with type 2diabetes mellitus and chronic kidney disease: an approach for the nephrologist PDB-101: Molecule of the Month:
Description
Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c)
It activates GLP-1 receptors, leading to increased insulin release from pancreatic beta cells in response to elevated blood sugar levels, making it an excellent treatment for type 2 diabetes
Because the medicine enters the fatty tissue directly, it bypasses the digestive system and the livers first-pass metabolism
Large-scale, multi-center studies and clinical trials will be essential to confirm these findings and refine guidelines for patients at risk
The challenges and opportunities associated with reimbursement for obesity pharmacotherapy in the USA
The Lancet Gastroenterology & Hepatology, 2024
